Skip to main content
SpringerLink
Log in

Cutaneous Lupus Erythematosus

Diagnosis and Management

  • Therapy in Practice
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Cutaneous lupus erythematosus (CLE) includes a variety of lupus erythematosus (LE)-specific skin lesions that are subdivided into three categories — chronic CLE (CCLE), subacute CLE (SCLE) and acute CLE (ACLE) — based on clinical morphology, average duration of skin lesions and routine histopathologic examination.

This paper describes our personal experience in the management of CLE over the last 30 years, with details on preferential therapeutic options related to clinical, histologic and immunopathologic aspects of each clinical subset of the disease.

Effective sunscreening and sun protection are considered the first rule in the management of CLE because of the high degree of photosensitivity of the disease. Antimalarial agents are crucial in the treatment of CLE and are the first-line systemic agents, particularly in discoid LE (DLE) and SCLE.

Dapsone is the drug of choice for bullous systemic LE (BSLE) as well as for LE in small dermal vessels (e.g. leukocytoclastic vasculitis). Retinoids, known as second-line drugs for systemic therapy, are sometimes used to treat chronic forms of CLE and are particularly successful in treating hypertrophic LE. Systemic immunosuppressive agents are required to manage the underlying systemic LE disease activity in patients with ACLE. These drugs, especially azathioprine, methotrexate, cyclophosphamide and cyclosporine, together with corticosteroids, constitute third-line systemic therapy of CLE. In our experience, oral prednisone or parenteral ‘pulsed’ methylprednisolone are useful in exacerbations of disease activity. Thalidomide provides one of the most useful therapeutic alternatives for chronic refractory DLE, although its distribution is limited to a few countries because of the risk of teratogenicity and polyneuropathy.

However, medical treatment with local corticosteroids remains the mainstay of CLE treatment, especially for DLE. Patient education regarding the disease is also important in the management of CLE, because it helps relieve undue anxiety and to recruit the patient as an active participant in the treatment regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Fig. 1
Table VI
Fig. 2
Table VII
Table VIII
Table IX
Fig. 3
Fig. 4
Table X
Fig. 5
Fig. 6
Table XI
Fig. 7
Fig. 8
Fig. 9
Table XII
Table XIII

Similar content being viewed by others

References

  1. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471–5

    Article  PubMed  CAS  Google Scholar 

  2. Cardinali C, Caproni M, Bernacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus-the Italian experience. Lupus 2000; 9: 417–23

    Article  PubMed  CAS  Google Scholar 

  3. Rothfield NF. Chronic discoid lupus erythematosus. In: Fitzpatrick TB, Eisen AZ, Wolff K, Austen KF, editors. Dermatology in general medicine. New York: McGraw-Hill, 1993: 2137

    Google Scholar 

  4. Callen JP. Chronic cutaneous lupus erythematosus. Arch Derm 1982; 118: 412–6

    Article  PubMed  CAS  Google Scholar 

  5. Millard LG, Rowell NR. Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. Arch Dermatol 1979; 115: 1055–8

    Article  PubMed  CAS  Google Scholar 

  6. Rook A, Wilkinson DS, Ebling FJC. Textbook of dermatology. Oxford: Blackwell, 1992: 2171–4

    Google Scholar 

  7. Callen JP, Tuffanelli DL, Provost TT. Collagen-vascular disease: an update. J Am Acad Dermatol 1993; 28: 477–84

    Article  PubMed  CAS  Google Scholar 

  8. Su WP, Perniciaro C, Rogers RS, et al. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis 1994; 54: 395–9

    PubMed  CAS  Google Scholar 

  9. Sontheimer RD. The lexicon of cutaneous lupus erythematosus: a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 84–95

    Article  PubMed  CAS  Google Scholar 

  10. Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade’s perspective. Med Clin North Am 1989; 73: 1073–86

    PubMed  CAS  Google Scholar 

  11. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous disorder. J Invest Dermatol 1993; 100: 28S-34S

    Article  Google Scholar 

  12. Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995; 132: 921–8

    Article  PubMed  CAS  Google Scholar 

  13. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 1996; 34: 830–6

    Article  PubMed  CAS  Google Scholar 

  14. Millard TP, Hawk JLM, McGregor JM. Photosensitivity in lupus. Lupus 2000; 9: 3–10

    Article  PubMed  CAS  Google Scholar 

  15. Cardinali C, Caproni M, Fabbri P. The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus. Clin Exp Rheumatol 1999; 17: 427–32

    PubMed  CAS  Google Scholar 

  16. Cardinali C, Caproni M, Fabbri P. The composition of the lupus band test (LBT) on the sun-protected non-lesional (SPNL) skin in patients with cutaneous lupus erythematosus (CLE). Lupus 1999; 8: 755–60

    Article  PubMed  CAS  Google Scholar 

  17. Callen JP, Fowler JF, Kulick KB. Serologic and clinical features of patients with discoid lupus erythematosus: relationship of antibodies to single-stranded deoxyribonucleic acid and of other antinuclear antibody subsets to clinical manifestations. J Am Acad Dermatol 1985; 13: 748–55

    Article  PubMed  CAS  Google Scholar 

  18. Shrank AB, Doniach D. Discoid lupus erythematosus. Arch Dermatol 1963; 87: 677–85

    Article  PubMed  CAS  Google Scholar 

  19. Kimberly RE, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999; 41: 1049–50

    Article  Google Scholar 

  20. Werth V. Current treatment of cutaneous lupus erythematosus. Dermatol Online J 2001; 7 (1): 2

    PubMed  CAS  Google Scholar 

  21. Sontheimer RD. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary? Arch Dermatol 2000; 136: 1044–9

    Article  PubMed  CAS  Google Scholar 

  22. Karim MY, Ruiz-Irastorza G, Khamashta MA, et al. Update on the therapy-thalidomide in the treatment of lupus. Lupus 2001; 10: 188–92

    Article  PubMed  CAS  Google Scholar 

  23. Ordi-Ros J, Cortes F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000; 27: 1429–33

    PubMed  CAS  Google Scholar 

  24. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000; 39: 218–22

    Article  PubMed  CAS  Google Scholar 

  25. Delaporte E, Catteau B, Sabbagh N, et al. Treatment of discoid lupus erythematosus with sulfasalazine. Ann Dermatol Venereol 1997; 124: 151–6

    PubMed  CAS  Google Scholar 

  26. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45: 142–4

    Article  PubMed  CAS  Google Scholar 

  27. Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral compound (auranofin). Br J Dermatol 1986; 115: 211–6

    Article  PubMed  CAS  Google Scholar 

  28. Kuhn A, Becker-Wegerich PM, Ruzika T, et al. Successful treatment of discoid lupus erythematosus with argon laser. Dermatology 2000; 201: 175–7

    Article  PubMed  CAS  Google Scholar 

  29. Mascaro JM, Herrero C, Hausmann G. Uncommon cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 122–31

    Article  PubMed  CAS  Google Scholar 

  30. Callen JP. Discoid lupus erythematosus: variants and clinical associations. In: Callen JP, editor. Clinics in Dermatology. Philadelphia: Lippincott JB, 1985: 49–57

    Google Scholar 

  31. Spann CR, Callen JP, Klein JB, et al. Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions. J Rheumatol 1988; 15: 256–61

    PubMed  CAS  Google Scholar 

  32. Uitto J, Santa-Cruz DJ, Eisen AZ, et al. Verrucous lesion in patients with discoid lupus erythematosus: clinical, histopathological and immunofluorescence studies. Br J Dermatol 1978; 98: 507–20

    Article  PubMed  CAS  Google Scholar 

  33. Santa-Cruz DJ, Uitto J, Eisen AZ, et al. Verrucous lupus erythematosus: ultrastructural studies on a distinct variant of chronic discoid lupus erythematosus. J Am Acad Dermatol 1983; 9: 82–90

    Article  PubMed  CAS  Google Scholar 

  34. Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol 1976; 94: 51–8

    Article  PubMed  Google Scholar 

  35. Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991; 47: 351–5

    PubMed  CAS  Google Scholar 

  36. Green S, Piette W. Treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol 1987; 17: 364–8

    Article  PubMed  CAS  Google Scholar 

  37. Izumi AK, Takiguchi P. Lupus erythematosus panniculitis. Arch Dermatol 1983; 119: 61–4

    Article  PubMed  CAS  Google Scholar 

  38. Sanchez NP, Peters MS, Winklemann RK. The histopathology of lupus erythematosus panniculitis. J Am Acad Dermatol 1981; 5: 673–80

    Article  PubMed  CAS  Google Scholar 

  39. Yamada Y, Dekio S, Jidoi J, et al. Lupus erythematosus profundus -report of a case treated with dapsone. J Dermatol 1989; 16: 379–82

    PubMed  CAS  Google Scholar 

  40. Burrows NP, Walport MJ, Hammond AH, et al. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol 1991; 125: 62–7

    Article  PubMed  CAS  Google Scholar 

  41. Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson): a clinical and laboratory study of 17 patients. Br J Dermatol 1978; 98: 497–506

    Article  PubMed  CAS  Google Scholar 

  42. Doutre MS, Beylot C, Beylot J, et al. Chilblain lupus erythematosus: report of 15 cases. Dermatology 1992; 184: 26–8

    Article  PubMed  CAS  Google Scholar 

  43. Aoki T, Ishizawa T, Hozumi Y, et al. Chilblain lupus erythematosus of Hutchinson responding to surgical treatment: a report of two patients with anti-Ro/SSA antibodies. Br J Dermatol 1996; 134: 533–7

    Article  PubMed  CAS  Google Scholar 

  44. Allegue F, Alonso ML, Rocamora A, et al. Chilblain lupus erythematosus and antiphospholipid antibody syndrome. J Am Acad Dermatol 1988; 19: 908–10

    Article  PubMed  CAS  Google Scholar 

  45. Rowell NR. Chilblain lupus erythematosus responding to etretinate. Br J Dermatol 1987; 117: 100–2

    Article  Google Scholar 

  46. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001; 137: 235–6

    PubMed  CAS  Google Scholar 

  47. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus -review of 60 patients. Photochem Photobiol 2001; 73: 532–6

    Article  PubMed  CAS  Google Scholar 

  48. Goerz G, Lehmann P, Schuppe HC, et al. Lupus erythematosus. Z Hautkr 1990; 65: 229–34

    Google Scholar 

  49. Kind P, Goerz G. Der kutane lupus erythematodes (LE). In: Macher E, Knop J, Bröcker EB, editors. Jahrbuch der Dermatologie. Münster, Germany: Biermann Verlag, 1988: 85–103

    Google Scholar 

  50. Kind P, Schuppe HC, Goerz G. Kutaner Lupus erythematodes. Dtsch Ärztebl 1992; 49: 2121–30

    Google Scholar 

  51. Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus: a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033–41

    Article  PubMed  CAS  Google Scholar 

  52. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409–15

    Article  PubMed  CAS  Google Scholar 

  53. Callen JP, Klein J. Subacute cutaneous lupus erythematosus: clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988; 31: 1007–13

    Article  PubMed  CAS  Google Scholar 

  54. Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol 1994; 21: 1665–9

    PubMed  CAS  Google Scholar 

  55. Fabbri P, Bernacchi E, Neri R. Subacute cutaneous lupus erythematosus: review of the literature and immunological studies of 11 patients. G Ital Dermatol Venereol 1990; 125: 329–36

    PubMed  CAS  Google Scholar 

  56. David-Bajar KM. What’s new in cutaneous lupus syndromes: subacute cutaneous lupus erythematosus. J Invest Dermatol 1993; 100: 2s-8s

    Article  Google Scholar 

  57. Parodi A, Caproni M, Cardinali C, et al. Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus: a review by the Italian Group of Immunodermatology. Dermatology 2000; 200: 6–10

    Article  PubMed  CAS  Google Scholar 

  58. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103: 49–51

    PubMed  CAS  Google Scholar 

  59. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol 2001; 137: 1196–8

    PubMed  CAS  Google Scholar 

  60. Bonsmann G, Schiller M, Luger TA, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001; 44: 925–31

    Article  PubMed  CAS  Google Scholar 

  61. Despain J, Clark DP. Subacute cutaneous lupus erythematosus presenting as erythroderma. J Am Acad Dermatol 1988; 19: 388–92

    Article  PubMed  CAS  Google Scholar 

  62. Bielsa I, Herrero C, Font J, et al. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol 1987; 16: 1265–7

    Article  PubMed  CAS  Google Scholar 

  63. Jenkins RE, Kurwa AR, Atherton DJ, et al. Neonatal lupus erythematosus. Clin Exp Dermatol 1994; 19: 409–11

    Article  PubMed  CAS  Google Scholar 

  64. Scheinman PL. Acral subacute cutaneous lupus erythematosus: an unusual variant. J Am Acad Dermatol 1994; 30: 800–1

    Article  PubMed  CAS  Google Scholar 

  65. Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996; 35: 313–5

    Article  PubMed  CAS  Google Scholar 

  66. Pramatarov K, Vassileva S, Miteva L. Subacute cutaneous lupus erythematosus presenting with generalized poikiloderma. J Am Acad Dermatol 2000; 42: 286–8

    Article  PubMed  CAS  Google Scholar 

  67. Lever WF, Schaumburg-Lever G. Connective tissue diseases. In: Lever WF, Schaumburg-Lever G, editors. Histopathology of the skin. 7th ed. Philadelphia: JB Lippincott Company, 1989: 494–522

    Google Scholar 

  68. Nieboer C, Tak-Diamand Z, Vanleeuwen-Wallau HE. Dust-like particles: a specific direct immunofluorescence pattern in subacute cutaneous lupus erythematosus. Br J Dermatol 1988; 194: 217–20

    Google Scholar 

  69. Alspaugh MA, Talal N, Tan EM. Differentiation and characterization of autoantibodies and their antigens in Sjögren’s syndrome. Arthritis Rheum 1976; 19: 216–22

    Article  PubMed  CAS  Google Scholar 

  70. Scopelitis E, Biundo JJ, Alspaugh MA. Anti-SSA antibody and other antinuclear antibodies in systemic lupus erythematosus. Arthritis Rheum 1980; 23: 287–93

    Article  PubMed  CAS  Google Scholar 

  71. Jenkins RE, Kurwa AR, Atherton DJ, et al. Neonatal lupus erythematosus. Clin Exp Dermatol 1994; 19: 409–11

    Article  PubMed  CAS  Google Scholar 

  72. Reichlin M. Clinical and immunological significance of antibodies to Ro and La in systemic lupus erythematosus. Arthritis Rheum 1982; 25: 767–72

    Article  PubMed  CAS  Google Scholar 

  73. Jones SK. Ultraviolet radiation (UVR) induces cell-surface Ro/SSA antigen expression by human keratinocytes in vitro: a possible mechanism for the UVR cutaneous lesions. Br J Dermatol 1992; 126: 546–53

    Article  PubMed  CAS  Google Scholar 

  74. Versapuech J, Beylot-Barry M, Doutre MS, et al. Subacute cutaneous lupus: evolutive and therapeutic features of a series of 24 cases. Presse Med 2000; 29: 1596–9

    PubMed  CAS  Google Scholar 

  75. Doutre MS, Beylot-Barry M, Beylot C. Subacute cutaneous lupus erythematosus. Presse Med 2000; 29: 1311–6

    PubMed  CAS  Google Scholar 

  76. Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 1990; 29: 587–90

    Article  PubMed  CAS  Google Scholar 

  77. Kuhn A, Specker C, Ruzicka T, et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002; 46: 600–3

    Article  PubMed  Google Scholar 

  78. Bohm L, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997; 194: 307–8

    Article  PubMed  CAS  Google Scholar 

  79. Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatology 1995; 190: 277–83

    Article  PubMed  CAS  Google Scholar 

  80. Wysenbeek AJ, Guedj D, Amit M, et al. Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations. Ann Rheum Dis 1992; 51: 717–9

    Article  PubMed  CAS  Google Scholar 

  81. Chlebus E, Wolska H, Blaszczyk M, et al. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol 1998; 38: 405–12

    Article  PubMed  CAS  Google Scholar 

  82. Antolin J, Amerigo MJ, Cantabrana A, et al. Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients: subgroup classification of SLE. Clin Rheumatol 1995; 14: 678–85

    Article  PubMed  CAS  Google Scholar 

  83. McCurdy DK, Bick M, Gatti RA, et al. Autoantibodies in systemic lupus erythematosus. Dis Markers 1992; 10: 37–49

    PubMed  CAS  Google Scholar 

  84. Neri R, Tavoni A, Cristofani R, et al. Antinuclear antibody profile in Italian patients with connective tissue diseases. Lupus 1992; 1: 221–7

    Article  PubMed  CAS  Google Scholar 

  85. Somanathan S, Suchyna TM, Siegel AJ, et al. Targeting of PCNA to sites of DNA replication in the mammalian cell nucleus. J Cell Biochem 2001; 81: 56–67

    Article  PubMed  CAS  Google Scholar 

  86. Sturfelt G, Bengtsson A, Klint C, et al. Novel roles of complement in systemic lupus erythematosus -hypothesis for a pathogenetic vicious circle. J Rheumatol 2000; 27: 661–3

    PubMed  CAS  Google Scholar 

  87. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7

    Article  PubMed  CAS  Google Scholar 

  88. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996; 135: 355–62

    Article  PubMed  CAS  Google Scholar 

  89. Braverman IM. Connective tissue (rheumatic) diseases. In: Braverman IM, editor. Skin signs of systemic disease. Philadelphia: WB Saunders Company, 1981: 255–377

    Google Scholar 

  90. Cardinali C, Giomi B, Caproni M, et al. Maculopapular lupus rash in a young woman with systemic involvement. Lupus 2000; 9: 713–6

    Article  PubMed  CAS  Google Scholar 

  91. Booth SA, Moody CE, Dahl MV, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98: 135–40

    Article  PubMed  CAS  Google Scholar 

  92. Gammon WR, Briggaman RA. Bullous eruption of systemic lupus erythematosus. In: Wojnarowska F, Briggaman RA, editors. Management of blistering diseases. London: Chapman and Hall Ltd, 1990: 263–75

    Google Scholar 

  93. Davies MG, Marks R, Waddington E. Simultaneous systemic lupus erythematosus and dermatitis herpetiformis. Arch Dermatol 1976; 112: 1292–4

    Article  PubMed  CAS  Google Scholar 

  94. Miller JF, Downham TF, Chapel TA. Coexistent bullous pemphigoid and systemic lupus erythematosus. Cutis 1978; 21: 368–73

    PubMed  CAS  Google Scholar 

  95. Blanchet PH, Auffret N, Fauchard J, et al. Association of thymoma with pemphigus foliaceous, nephrotic syndrome and lupus biology. Ann Dermatol Venereol 1981; 108: 471–2

    PubMed  CAS  Google Scholar 

  96. Dotson AD, Raimer SS, Pursley TV, et al. Systemic lupus erythematosus occurring in a patient with epidermolysis bullosa acquisita. Arch Dermatol 1981; 117: 422–6

    Article  PubMed  CAS  Google Scholar 

  97. Lau M, Kaufmann-Grunzinger I, Raghunath M. A case report of a patient with features of systemic lupus erythematosus and linear IgA disease. Br J Dermatol 1991; 124: 498–502

    Article  PubMed  CAS  Google Scholar 

  98. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993; 100: 28S-34S

    Article  Google Scholar 

  99. Gammon WR, Woodley DT, Dole KC, et al. Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigen. J Invest Dermatol 1985; 84: 472–6

    Article  PubMed  CAS  Google Scholar 

  100. Woodley D, Sauder D, Talley MJ, et al. Localization of basement membrane components after dermal-epidermal junction separation. J Invest Dermatol 1983; 81: 149–53

    Article  PubMed  CAS  Google Scholar 

  101. Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995; 132: 921–8

    Article  PubMed  CAS  Google Scholar 

  102. Asherson RA, Benbow A, Speirs CJ, et al. Pulmonary hypertension in hydralazine induced systemic lupus erythematosus: association with C4 null allele. Ann Rheum Dis 1986; 45: 771–3

    Article  PubMed  CAS  Google Scholar 

  103. Dodd HJ, Cox PM, Sarkany I. Bullous lesions in hydralazine induced lupus erythematosus -a review of three cases [abstract]. Br J Dermatol 1988; 119 Suppl. 33: 27

    Article  Google Scholar 

  104. Lewis Jones MS, Evans S, Thompson CM. Erythema multiforme occurring in association with lupus erythematosus drug therapy with doxycycline. Clin Exp Dermatol 1988; 13: 245–7

    Article  PubMed  CAS  Google Scholar 

  105. Peterson LL. Hydrallazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984; 10: 379–84

    Article  PubMed  CAS  Google Scholar 

  106. Crowson AN, Magro CM. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 1997; 28: 67–72

    Article  PubMed  CAS  Google Scholar 

  107. Buratti, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103–8

    PubMed  CAS  Google Scholar 

  108. Gaubitz M, Schorat A, Schotte H, et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731–6

    Article  PubMed  CAS  Google Scholar 

  109. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833–9

    PubMed  CAS  Google Scholar 

  110. Rutter A, Luger TA. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr Opin Investig Drugs 2002; 3: 713–9

    PubMed  CAS  Google Scholar 

  111. Zimmerman R, Radhakrishnan J, Valeri A, et al. Advances in the treatment of lupus nephritis. Annu Rev Med 2001; 52: 63–78

    Article  PubMed  CAS  Google Scholar 

  112. Stanislav ML, Balabanova RM, Nikonova MF, et al. Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus. Ter Arkh 2000; 72: 44–9

    PubMed  CAS  Google Scholar 

  113. Duna GF, Cash JM. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 1995; 21: 99–115

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Dermatological Sciences, University of Florence, Via degli Alfani 37, 50121, Florence, Italy

    Paolo Fabbri, Carla Cardinali, Barbara Giomi & Marzia Caproni

Authors
  1. Paolo Fabbri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carla Cardinali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Giomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marzia Caproni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carla Cardinali.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fabbri, P., Cardinali, C., Giomi, B. et al. Cutaneous Lupus Erythematosus. Am J Clin Dermatol 4, 449–465 (2003). https://doi.org/10.2165/00128071-200304070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200304070-00002

Keywords

Search

Navigation